ASK1 inhibition: a therapeutic strategy with multi-system benefits

Area of Science:

• Cellular Biology
• Molecular Medicine
• Drug Discovery

Background:

• p38 and c-Jun N-terminal kinases (JNK) are crucial for cellular stress response.
• Prolonged p38 and JNK signaling contribute to inflammation, cell death, and fibrosis, driving diseases like arthritis and dementia.
• Existing p38 and JNK inhibitors have shown limited success in treating these conditions.

Purpose of the Study:

• To review evidence linking apoptosis signal-regulating kinase 1 (ASK1) to detrimental p38 and JNK activation.
• To explore the therapeutic potential of ASK1 inhibition for diseases driven by these pathways.
• To summarize findings from preclinical and clinical studies of ASK1 inhibitors.

Main Methods:

• Literature review of studies on ASK1, p38, and JNK signaling pathways.
• Analysis of preclinical data from cell and animal models of disease.
• Examination of results from human clinical trials investigating ASK1 inhibitors.

Main Results:

• Evidence supports ASK1's role in mediating harmful cellular responses through sustained p38 or JNK activation.
• ASK1 inhibition demonstrates potential therapeutic benefits across various disease contexts.
• Studies in cell and animal models, as well as human trials, provide a basis for ASK1 as a drug target.

Conclusions:

• ASK1 is a promising therapeutic target for mitigating diseases associated with prolonged p38 and JNK signaling.
• Inhibition of ASK1 offers a potential strategy to address inflammatory, cell death, and fibrotic processes.
• Further research and clinical development of ASK1 inhibitors are warranted for treating a range of human disorders.